Key Quantitative Figures

Standalone Financial Results (Q1 FY27):

  • Revenue from Operations: ₹178.80 crore
  • Total Income: ₹181.35 crore
  • Total Expense: ₹148.75 crore
  • Profit Before Tax: ₹32.60 crore
  • Current Tax: ₹8.20 crore
  • Deferred Tax: (₹1.13) crore
  • Net Profit: ₹25.53 crore
  • EPS (Basic & Diluted): Not quantified in disclosure
  • EBIDTA: ₹39.11 crore

Consolidated Financial Results (Q1 FY27):

  • Revenue from Operations: ₹178.86 crore
  • Total Income: ₹181.48 crore
  • Total Expense: ₹151.44 crore
  • Profit Before Tax: ₹30.04 crore
  • Current Tax: ₹8.20 crore
  • Deferred Tax: (₹1.13) crore
  • Net Profit: ₹22.97 crore
  • EPS Basic: ₹17.18
  • EPS Diluted: Not separately quantified
  • EBIDTA: ₹36.81 crore

Dates of Action

  • Board Meeting Date: July 20, 2026 (commenced at 2:45 PM, concluded at 6:20 PM)
  • Quarter Ended: June 30, 2026
  • Trading Window Closure: July 1, 2026 to 48 hours after results declaration
  • Previous Communication: July 9, 2026 (regarding MOA revision)
  • Initial MOA Disclosure: May 26, 2026

Parties Involved

  • Subsidiaries: Venus Pharma GmbH (wholly owned, Germany), Venus Pharma Kft (step-down subsidiary, Hungary)
  • Statutory Auditor: J.K. Jain & Associates, Chartered Accountants
  • Financial Consultant: Germany-based firm engaged for European operations restructuring

Purpose and Rationale

MOA Revision:

To align Object Clause with Companies Act, 2013 provisions and update Main Objects and Incidental Objects to reflect current business practices and proposed activities. The principal business activities remain unchanged in the pharmaceutical sector.

European Operations:

Restructuring of European operations through Venus Pharma GmbH, with engagement of financial consultancy firm for appropriate framework and mechanism.

Financial and Operational Impact

Subsidiary Investment:

  • Outstanding share application money: ₹2,859.72 lakhs for Venus Pharma GmbH
  • Share allotment pending as not mandatory under German laws
  • Management considers investment strategic and intends to recover amount during FY 2026-27 restructuring
  • Subsidiary currently facing financial challenges
  • Company committed to providing financial and operational support during transition

Segment Information:

  • Single reportable segment: Pharmaceuticals

Capital Structure Impact

  • Paid-up equity share capital: ₹13.37 crore (face value ₹10 per share)
  • No change in share capital structure disclosed

Auditor's Emphasis

Auditor drew attention to the outstanding share application money for Venus Pharma GmbH, noting the investment is strategic and recovery is expected through restructuring. The conclusion was not modified regarding this matter.

Comparative Figures

Standalone Quarterly Comparison:

  • Q1 FY27 vs Q1 FY26: Revenue increased from ₹139.85 crore to ₹181.35 crore
  • Q1 FY27 vs Q4 FY26: Revenue decreased from ₹263.64 crore to ₹181.35 crore
  • Net Profit: Q1 FY27 ₹25.53 crore vs Q1 FY26 ₹11.70 crore vs Q4 FY26 ₹57.57 crore

Consolidated Quarterly Comparison:

  • Q1 FY27 vs Q1 FY26: Revenue increased from ₹140.59 crore to ₹181.48 crore
  • Q1 FY27 vs Q4 FY26: Revenue decreased from ₹264.35 crore to ₹181.48 crore
  • Net Profit: Q1 FY27 ₹22.97 crore vs Q1 FY26 ₹9.60 crore vs Q4 FY26 ₹47.49 crore

Forward-looking Information

Management reiterated intention to provide necessary financial and operational support to Venus Pharma GmbH during the transition period of European operations restructuring.